|
|
| | Carboxyatractyloside Basic information |
| | Carboxyatractyloside Chemical Properties |
| density | 1.58±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | H2O: ≥10mg/mL | | form | solid | | pka | -3+-.0.18(Predicted) | | color | white | | biological source | Xanthium sibiricum | | Optical Rotation | [α]/D -34 to -48°, c =0.5 in water | | Water Solubility | H2O: ≥10mg/mL |
| Hazard Codes | T | | Risk Statements | 23/24/25 | | Safety Statements | 36/37-45 | | RIDADR | UN 2811 6.1 / PGI | | WGK Germany | 3 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Dermal
Acute Tox. 3 Inhalation
Acute Tox. 3 Oral |
| | Carboxyatractyloside Usage And Synthesis |
| Chemical Properties | White powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Atractylodes lancea. | | Uses | Carboxyatractyloside potassium salt has been used as an activator of Ca2+-induced mPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) opening. It has also been used as a adenine nucleotide translocator (ANT) inhibitor to study the inhibition of oxidative phosphorylation in intact T98G glioma cells. | | Biochem/physiol Actions | Carboxyatractyloside is a highly selective inhibitor of cytosolic side-specific mitochondrial ADP/ATP carrier; i.e. adenine nucleotide translocase (ANT); causes stabilization of the c conformation of ANT leading to permeability transition pore (PTP) opening, loss of mitochondrial membrane potential, and apoptosis. | | target | Calcium Channel | P450 (e.g. CYP17) |
| | Carboxyatractyloside Preparation Products And Raw materials |
|